Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to “Buy” Rating by StockNews.com

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.

Several other research analysts have also recently weighed in on IRWD. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Wells Fargo & Company decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Craig Hallum decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Down 3.6 %

IRWD stock opened at $4.78 on Tuesday. Ironwood Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $15.70. The stock has a market cap of $763.56 million, a price-to-earnings ratio of -159.33 and a beta of 0.47. The business’s 50-day moving average is $4.32 and its 200 day moving average is $5.58.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company’s revenue for the quarter was down 19.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.12 earnings per share. As a group, equities analysts forecast that Ironwood Pharmaceuticals will post 0.26 EPS for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp raised its position in Ironwood Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock valued at $1,047,000 after purchasing an additional 1,557 shares during the period. CWM LLC increased its position in shares of Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 2,345 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Ironwood Pharmaceuticals by 3.5% during the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock worth $459,000 after acquiring an additional 2,400 shares during the period. SummerHaven Investment Management LLC increased its position in shares of Ironwood Pharmaceuticals by 3.6% during the second quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock worth $470,000 after acquiring an additional 2,491 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Ironwood Pharmaceuticals by 0.7% during the second quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock worth $2,384,000 after acquiring an additional 2,577 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.